GSK’s Nucala Phase III trial shows promise in treating chronic lung disease
September 6, 2024: UK pharmaceutical giant GSK (GSK.L) announced that its asthma medicine, Nucala (mepolizumab), has shown positive results in a late-stage clinical.
Drugs
Health
Pharma
Drugs
Medical
Pharma
GSK offloads 300 million shares in Haleon for $1.2 billion
HQ Team January 19, 2024: GSK is giving up more of its stake in Haleon, the consumer health business the British pharma giant.